EFFECT OF OXIRACETAM COMBINED WITH CITICOLINE SODIUM ON SERUM HS-CRP, GFAP, S100Β PROTEIN AND TAU PROTEIN IN PATIENTS WITH CEREBRAL HEMORRHAGE

Li Zhang¹, Ying Guo², Wen Zhang³, Guangxian Nan^{1, *}

¹Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, PR China - ²Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, PR China - ³Department of Norman Bethune College of Medicine of Jilin University, Changchun, PR China

Objective: To analyse the effects of oxiracetam combined with citicoline sodium on serum hs-CRP, glial fibrillary acidic protein (GFAP), S100β protein and tau protein in patients with cerebral haemorrhage. 

Methods: Eighty patients with cerebral haemorrhage were divided into a control group (n = 40) and an observation group (n = 40). The observation group was treated with oxiracetam combined with citicoline sodium, and the control group was treated with citicoline sodium alone. Serum hs-CRP levels were measured by immunoturbidimetric assay, and serum GFAP, S100β protein and tau protein levels were measured by enzyme-linked immunosorbent assay. 

Results: The amount of cerebral hematoma in the observation group at 2 and 3 weeks was significantly lower than that in the control group (P<0.01). The Barthel Index (BI) and Mini-Mental State Examination (MMSE) scores in the observation group were significantly higher than those in the control group (P<0.01). After treatment, the levels of hs-CRP, GFAP, S100β protein and tau protein in the observation group and the control group were significantly lower than those before treatment, and the levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the control group was 15.00% and 12.50% in the observation group. The difference was not statistically significant (P>0.05). 

Conclusions: Oxiracetam combined with citicoline sodium could effectively reduce the amount of cerebral hematoma and improve mental state and nerve function. The drugs significantly reduce the levels of hs-CRP, GFAP, S100β protein and tau protein and have a good safety profile.